Liberalised German market "to provide spur for medtech"
This article was originally published in Clinica
BVMed industry association chairman Anton Schmidt (Johnson & Johnson) believes that a deregulated and liberalised healthcare market, with bureaucracy cut away, would provide optimum conditions for the introduction of more medical technology innovations.
You may also be interested in...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.